Effect of acetazolamide and furosemide in combination for acute heart failure with volume overload under sodium glucose co-transportor 2 inhibitor

Phase 4

Recruiting

• Conditions: Acute heart failure; D006333

• Registration Number: JPRN-jRCTs031230483
• Lead Sponsor: Iwahana Togo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-29
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1) A patient aged 18 years or older at the time of enrollment.
2) A patient hospitalized for acute heart faiure based on Framingham criteria.
3) NT-proBNP > 1000pg/mL or BNP > 250pg/mL
4) A patient who has clinical sign of volume overload. (edema, pleural effusion, ascites or juglar vein retension).
5) A patients who have taken sodium glucose co-transportor 2 inhibitors (dapagliflozin or empagliflozin) for at least 1 month.
6) A patient who has provided written informed consent to participate in this study (if the patient can not sign by oneself, it is acceptable that a family or a person following a family writes on behalf).

Exclusion Criteria

1) Receipt of acetazolamide maintenance therapy or intolerance for acetazolamide
2) Type 1 diabetes
3) Symptomatic hypotension
4) A Patient expected to receive intravenous inotropes
5) A history of acute coronary syndrome, stroke or transient ischemic attack within 3 months before screening.
6) A history of allergy for sodium glucose co-transportor 2 inhibitor or acetazolamide
7) Restrictive cardiomyopathy, active myocarditis or hypertrophic obstructive cardiomyopathy
8) Na >145 mEq/L, Na < 130 mEq/L or K < 3.0 mEq/L
9) Severe hepatic dysfunction (Child-Pugh class C)
10) Severe chronic kidney disease (Cre > 3.5mg/dL, eGFR < 20mL/min/1.73m2)
11) Anurea or hypourea (daily urine output < 400mL)
12) Renal replacement therapy
13) Pregnant, possibly pregnant, within 28 days postpartum or nursing women
14) A patient whom the investigator considers to be ineligible as a subject

Study & Design

• Study Type: Interventional
• Study Design: Not specified